BioNumerik Pharmaceuticals, Inc.

BioNumerik Pharmaceuticals, Inc.

BioNumerik Pharmaceuticals does biopharmaceutical drug development by the numbers. Using a multi-discipline process of identifying potential cancer drugs, the company has brought two candidates into late-stage development. Lead candidate Tavocept, which has FDA fast-track status, may prevent nerve and kidney damage caused by cancer therapies. BioNumerik's Karenitecin candidate is an advanced formulation of an existing cancer drug and is being evaluated for treatment of solid tumors. The firm relies heavily on computer models and simulations to identify promising drug candidates. In addition to its two lead candidates, it has several other potential drugs in pre-clinical research.

Contact Details

Office Address

BioNumerik Pharmaceuticals, Inc.
8122 Datapoint Drive, Suite 1250
San Antonio, TX, USA 78229
Phone: (210) 614-1701
Fax: (210) 615-8030

Executives

Chairman and CEO

Frederick H. Hausheer

VP Clinical Product Development

Stacey Bain

Business Reviews for BioNumerik Pharmaceuticals, Inc.

Related Companies